M. Murray

Alzheimer's disease heterogeneity and co‐pathologies: Defining novel targets, biomarkers, modalities, and research methodologies

Key takeaways from the Fall 2025 AARR meeting are presented, which brought together academic, clinical, and industry leaders to discuss and explore the current advances in the heterogeneity and co‐pathologies of AD and their implications for diagnosis, clinical trial design, and precision treatment strategies.

Atypical Alzheimer disease: a multi-axis framework toward defining heterogeneity.

Brain multiomic profiling identifies tau-related transcriptomic dysregulation in Alzheimer’s disease

A hypothetical model of dynamic brain gene expression changes that track with progressive Alzheimer’s disease proteostasis is proposed and found that a beneficial brain biochemical state of higher total tau and lower phospho-Tau is associated with increased levels of synaptic, DNA damage/repair, nucleic acid metabolism...